Citations

Clear

590 citation(s) found for "Ho, Ben".

The Global Incidence of Peptic Ulcer Disease Is Decreasing Since the Turn of the 21st Century: A Study of the Organisation for Economic Co-Operation and Development (OECD)
Azhari, Hassan, King, James A. , Mak, Joyce W.Y., Ben‐Horin, Shomron , Loftus, Edward V. , Burisch, Johan , Lakatos, Péter L. , Padilla, Francisco Javier Bosques, Underwood, Fox E., Kaplan, Gilaad G , Loftus, Edward V , King, James , Lakatos, Peter L , Coward, Stephanie B. , Windsor, Joseph W. , Ma, Christopher , Shah, Shailja C. , Ng, Siew C. , Mak, Joyce Wing Yan , Kotze, Paulo Gustavo , Lees, Charlie W. , Gearry, Richard B. , Calvet, Xavier , Kaplan, Gilaad G.

Mayo Clinic

American Journal of Gastroenterology | June 2, 2022 | Volume: 117 | Issue: 9 | Pages: 1419-1427

10.14309/ajg.0000000000001843 | PMID 35973143 Get It

INTRODUCTION: Peptic ulcer disease (PUD) is a common cause of hospitalization worldwide. We assessed temporal trends in hospitalization for PUD in 36 Organisation for Economic Co-operation and Development (OECD) countries since the turn of the 21st century. METHODS: The OECD database contains data on PUD-related hospital discharges and mortality for 36 countries between 2000 and 2019. Hospitalization rates for PUD were expressed as annual rates per 100,000 persons. Joinpoint regression models were used to calculate the average annual percent change (AAPC) with 95% confidence intervals (CIs) for each country, which were pooled using meta-analyses. The incidence of PUD was forecasted to 2021 using autoregressive integrated moving average and Poisson regression models. RESULTS: The overall median hospitalization rate was 42.4 with an interquartile range of 29.7–60.6 per 100,000 person-years. On average, hospitalization rates (AAPC = −3.9%; 95% CI: −4.4, −3.3) and morality rates (AAPC = −4.7%; 95% CI: −5.6, −3.8) for PUD have decreased from 2000 to 2019 globally. The forecasted incidence of PUD hospitalizations in 2021 ranged from 3.5 per 100,000 in Mexico to 92.1 per 100,000 in Lithuania. Across 36 countries in the OECD, 329,000 people are estimated to be hospitalized for PUD in 2021. DISCUSSION: PUD remains an important cause of hospitalization worldwide. Reassuringly, hospitalizations and mortality for PUD have consistently been falling in OECD countries in North America, Latin America, Europe, Asia, and Oceania. Identifying underlying factors driving these trends is essential to sustaining this downward momentum.
The Development of Novel Drug Treatments for Stroke Patients: A Review
Frank, Dmitry , Boyko, Matthew , Gruenbaum, Benjamin F. , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich

Mayo Clinic

International Journal of Molecular Sciences | May 21, 2022 | Volume: 23 | Issue: 10 | Pages: 5796

10.3390/ijms23105796 | PMID 35628606 Get It

Acute ischemic stroke is a critical condition that can result in disability and death. The consequences of this medical condition depend on various factors, including the size of the stroke, affected brain region, treatment onset, and the type of treatment. The primary objective of stroke treatment is to restart ischemic penumbra tissue perfusion and reduce infarct volume by sustaining blood flow. Recent research on the condition’s pathological pathways and processes has significantly improved treatment options beyond restoring perfusion. Many studies have concentrated on limiting injury severity via the manipulation of molecular mechanisms of ischemia, particularly in animal research. This article reviews completed and ongoing research on the development of acute ischemic stroke drugs. This study focuses on three main categories of antithrombotic drugs, thrombolytic drugs, and neuroprotective agents. The paper outlines findings from animal and clinical trials and explores the working mechanisms of these drugs.
Glutamate Efflux across the Blood–Brain Barrier: New Perspectives on the Relationship between Depression and the Glutamatergic System
Gruenbaum, Benjamin F. , Frenkel, Amit , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Frenkel, Amit , Boyko, Matthew , Zlotnik, Alexander Anatolievich , Fleidervish, Ilya A.

Mayo Clinic

Metabolites | May 20, 2022 | Volume: 12 | Issue: 5 | Pages: 459

10.3390/metabo12050459 | PMID 35629963 Get It

Depression is a significant cause of disability and affects millions worldwide; however, antidepressant therapies often fail or are inadequate. Current medications for treating major depressive disorder can take weeks or months to reach efficacy, have troubling side effects, and are limited in their long-term capabilities. Recent studies have identified a new set of glutamate-based approaches, such as blood glutamate scavengers, which have the potential to provide alternatives to traditional antidepressants. In this review, we hypothesize as to the involvement of the glutamate system in the development of depression. We identify the mechanisms underlying glutamate dysregulation, offering new perspectives on the therapeutic modalities of depression with a focus on its relationship to blood–brain barrier (BBB) permeability. Ultimately, we conclude that in diseases with impaired BBB permeability, such as depression following stroke or traumatic brain injury, or in neurogenerative diseases, the glutamate system should be considered as a pathway to treatment. We propose that drugs such as blood glutamate scavengers should be further studied for treatment of these conditions.
A Multicenter Comparison of Open Versus Arthroscopic Fixation for Pediatric Tibial Spine Fractures
Shimberg, Jilan L. , Leska, Tomasina M. , Ellis, Henry B. , Ganley, Theodore J. , Johnson, Ben, Milbrandt, Todd A. , Aoyama, Julien T. , Kushare, Indranil , Lee, R. Jay, Sachleben, Brant , Schmale, Gregory A. , Traver, Jessica L. , Mistovich, R. Justin , Cruz, Aristides I. , Patel, Neeraj M. , Fabricant, Peter D , Green, Daniel W , Lee, Rushyuan Jay , McKay, Scott , Rhodes, Jason T. , Yen, Yi‐Meng

Mayo Clinic

Orthopaedic Journal of Sports Medicine | May 18, 2022 | Volume: 10 | Issue: 5_suppl2 | Pages: No page available

10.1177/2325967121s00413 Get It

Background: When operative treatment is indicated, tibial spine fractures can be successfully managed with open or arthroscopic reduction and internal fixation. Hypothesis/Purpose: We hypothesized both approaches can lead to satisfactory outcomes for fracture healing, but that open treatment without preoperative advanced imaging can potentially lead to missed concomitant injuries. Methods: We performed an Institutional Review Board (IRB)-approved retrospective cohort study of pediatric tibial spine fractures presenting between January 1, 2000 and January 31, 2019 at 10 institutions. Patients were categorized into two cohorts based on treatment: arthroscopic reduction and internal fixation (ARIF) and open reduction and internal fixation (ORIF). Surgical outcomes, the incidence of concomitant injuries, and surgeon demographics were compared between groups. Results: There were 477 patients with tibial spine fractures who met inclusion criteria, 420 of whom (88.1%) were treated with ARIF, while 57 (11.9%) were treated with ORIF. Patients treated with ARIF were more likely to have an identified concomitant injury (41.4%) compared to those treated with ORIF (24.6%, p=0.021). Patients treated with ARIF were also more likely to have pre-treatment MRI (41.7% vs. 22.8%, p =0.010). Most concomitant injuries (74.5%) required surgical intervention. The most common treatment complications included arthrofibrosis (6.9% in ARIF patients, 7.0% in ORIF patients, p=1.00) and subsequent ACL injury (2.1% in ARIF patients and 3.5% in ORIF, p=0.86). The rate of complications, return to the operating room, and failure to return to full range of motion were similar between groups. Twenty surgeons with sports subspecialty training completed 85.0% of ARIF cases; the remaining 15.0% were performed by 12 surgeons without additional sports training. The majority (56.1%) of ORIF cases were completed by 14 surgeons without sports subspecialty training. Conclusion: This is the largest study comparing ARIF to ORIF in pediatric tibial spine fractures. This study demonstrated no difference in outcomes or nonunion following ARIF or ORIF for pediatric tibial spine fractures. There were significantly higher rates of concomitant injuries in patients treated with ARIF, however, these patients also had a higher rate of pre-treatment MRI. The majority of these concomitant injuries (74.5%) required surgical intervention. Pre-treatment MRI should be considered in the workup of tibial spine fractures to increase identification of concomitant injury. Concomitant injuries may be missed in tibial spine fractures treated with an open approach, especially in cases where preoperative advanced imaging is not obtained. Surgeon preference and training may impact treatment approach and identification and treatment of concomitant injury.
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
Gounder, Mrinal M. , Razak, Albiruni Abdul , Somaiah, Neeta , Chawla, Sant P. , Martín‐Broto, Javier , Schuetze, Scott M. , Vincenzi, Bruno , Wagner, Andrew J. , Chmielowski, Bartosz , Jones, Robin L. , Riedel, Richard F. , Stacchiotti, Silvia , Ganjoo, Kristen N. , Cesne, Axel Le , Italiano, Antoîne , Ryan, Christopher W. , Mulcahy, Mary F. , Forscher, Charles, Okuno, Scott H. , Hartner, Lee , Philip, Tony , Alcindor, Thierry , Reichardt, Peter , Chevreau, Christine , Morales, Claudia Maria Valverde, Chen, James L. , Deshpande, Hari A. , Nicholas, Garth , Gröschel, Stefan , Hatcher, Helen, Duffaud, Florence , Beveridge, Roberto Díaz, Meyer, Christian F. , Götze, Katharina S. , Mazzeo, F , Yakobson, Alexander, Zick, Aviad , Lee, Alexander T.J. , Estival, Anna , Napolitano, Andrea , Dickson, Mark A. , Michel, Dayana , Meng, Changting , Ben‐Shahar, Osnat , Chang, Hua, Landesman, Yosef , Shah, Jatin J., Shacham, Sharon, Kauffman, Michael , Attia, Steven , Schuetze, Scott M , Vincenzi, Bruno , Wagner, Andrew J , Chmielowski, Bartosz , Jones, Robin L , Riedel, Richard F , Loggers, Elizabeth T , Le Cesne, Axel , Italiano, Antoine , Garcia Del Muro, Xavier , Mulcahy, Mary F , Penel, Nicolas , Okuno, Scott , Elias, Anthony D , Hartner, Lee , Philip, Tony , Alcindor, Thierry , Lapeire, Lore , Blay, Jean-Yves , Chen, James L , Davis, Elizabeth J , Hatcher, Helen , Meyer, Christian , von Mehren, Margaret , Van Tine, Brian A , Götze, Katharina , Mazzeo, Filomena , Zick, Aviad , Lee, Alexander , Gonzalez, Anna Estival , Napolitano, Andrea , Michel, Dayana , Meng, Changting , Ben-Shahar, Osnat , Van Domelen, Dane R , Grignani, Giovanni , Burgess, Melissa , Piperno‐Neumann, Sophie , Elias, Anthony , Kasper, Bernd , Blay, Jean‐Yves , Schwartz, Gary K. , Davis, Elizabeth J. , Casado, Antonio , Badalamenti, Giuseppe , Eriksson, Mikael , Mehren, Margaret von , Tine, Brian A. Van , Li, Lingling , Liu, Jianjun , Walker, Christopher James

Mayo Clinic

Journal of Clinical Oncology | April 8, 2022 | Volume: 40 | Issue: 22 | Pages: 2479-2490

10.1200/jco.21.01829 | PMID 35394800 Get It

PURPOSE Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents. METHODS SEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT02606461 ). RESULTS Two hundred eighty-five patients were enrolled (selinexor, n = 188; placebo, n = 97). PFS was significantly longer with selinexor versus placebo: hazard ratio (HR) 0.70 (95% CI, 0.52 to 0.95; one-sided P = .011; medians 2.8 v 2.1 months), as was time to next treatment: HR 0.50 (95% CI, 0.37 to 0.66; one-sided P < .0001; medians 5.8 v 3.2 months). With crossover, no difference was observed in overall survival. The most common treatment-emergent adverse events of any grade versus grade 3 or 4 with selinexor were nausea (151 [80.7%] v 11 [5.9]), decreased appetite (113 [60.4%] v 14 [7.5%]), and fatigue (96 [51.3%] v 12 [6.4%]). Four (2.1%) and three (3.1%) patients died in the selinexor and placebo arms, respectively. Exploratory RNA sequencing analysis identified that the absence of CALB1 expression was associated with longer PFS with selinexor compared with placebo (median 6.9 v 2.2 months; HR, 0.19; P = .001). CONCLUSION Patients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation of CALB1 expression as a predictive biomarker for selinexor in DD-LPS is warranted.
Level I PD‐MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia
Boel, Judith A., Bie, Rob M.A. de , Schmand, Ben , Dalrymple‐Alford, John C. , Adler, Charles H. , Goldman, Jennifer G. , Tröster, Alexander I. , Geurtsen, Gert J. , Disease, MDS Study Group Mild Cognitive Impairment in Parkinson's, Halliday, Glenda M. , Antonini, Angelo , Lewis, Simon J.G. , Biundo, Roberta , Segura, Bàrbara , Williams‐Gray, Caroline H. , de Bie, Rob M A , Adler, C H , Geurtsen, Gert J , Halliday, Glenda , Goldman, Jennifer G , Antonini, Angelo , Dalrymple-Alford, John C , Lewis, Simon J G , Williams-Gray, Caroline H , Segura, Barbara , Marras, Connie , Burn, David J. , Litvan, Irene , Disease, MDS Study Group Mild Cognitive Impairment in Parkinson's

Mayo Clinic

Movement Disorders Clinical Practice | April 5, 2022 | Volume: 9 | Issue: 4 | Pages: 479-483

10.1002/mdc3.13451 | PMID 35582313 Get It

ABSTRACTBackgroundThe criteria for PD‐MCI allow the use of global cognitive tests. Their predictive value for conversion from PD‐MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown.MethodsThe MDS PD‐MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD‐MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD.ResultsPD‐MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P = <0.001). The C‐statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II.ConclusionMMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD‐MCI.
Reply to A. Smith et al
Fontana, Elisa , Meyers, Jeffrey P., André, Thierry , Ben‐Aharon, Irit , Shi, Qian , André, Thierry , Shi, Qian , Fontana, Elisa

Mayo Clinic

Journal of Clinical Oncology | March 22, 2022 | Volume: 40 | Issue: 16 | Pages: 1844-1846

10.1200/jco.22.00246 | PMID 35316071 Get It

Abstract 10663: Outcomes After Heart Transplantation in Patients with Cardiac Sarcoidosis
Alnsasra, Hilmi , Doulamis, Ilias P. , Kushwaha, Sudhir S. , Álvarez, Paulino , Asleh, Rabea , Kampaktsis, Polydoros Ν. , Briasoulis, Αlexandros

Mayo Clinic

Circulation | March 19, 2022 | Volume: 144 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.144.suppl_1.10663 Get It

Introduction: The number of patients with sarcoidosis requiring heart transplantation (HT) is on the rise. Hypothesis: The aim of this study was to evaluate outcomes of isolated HT in patients with sarcoid cardiomyopathy. Methods: Adult HT recipients were identified in the UNOS Registry between 1990 and 2020. Patients were grouped according to diagnosis. The cumulative incidences for the all-cause mortality and rejection were compared using Fine and Gray model analysis, accounting for re-transplantation as a competing risk. Moreover, we reviewed characteristics and outcomes of all HT recipients with previous diagnosis of sarcoid cardiomyopathy from a single-center. Results: A total of 30,874 HT recipients were included in the present study (n=240 sarcoidosis, n=1,431 non-ischemic restrictive cardiomyopathy, and n=29,203 non-ischemic dilated cardiomyopathy). During a total of 196,985 patient-years, all-cause mortality at the latest follow-up was not significantly different when comparing sarcoidosis to non-ischemic dilated cardiomyopathy (adjusted subhazard ratio [aSHR] 1.4, 95% confidence intervals [CI]: 0.88-2.3, p=0.15) or restrictive cardiomyopathy (aSHR 1.12, 95% CI: 0.65-1.95, p=0.67). Accordingly, multivariable analysis suggested that 1-year mortality was not significantly different between sarcoidosis and non-ischemic dilated cardiomyopathy (aSHR 1.56, 95% CI: 0.9-2.7, p=0.12) or restrictive (aSHR 1.15, 95% CI: 0.61-2.18, p=0.66) cardiomyopathy. Additionally, no differences were observed regarding 30-day mortality after HT. Data from the single-center case review showed excellent long-term outcomes with sirolimus-based immunosuppression. Conclusions: Short- and long-term outcomes after isolated HT do not seem to be inferior in sarcoid cardiomyopathy when compared to common types of non-ischemic cardiomyopathy.
Abstract 17604: Identification of Genotype-specific Electrocardiogram Patterns in Long QT Syndrome Using a Novel, Automated T Wave Analysis Program
Sugrue, Alan , Qiang, Bo , Friedman, Paul A. , Ackerman, Michael J. , Bos, J. Martijn , Křemen, Václav , Qiang, Bo, Noseworthy, Peter A.

Mayo Clinic

Circulation | March 19, 2022 | Volume: 132 | Issue: suppl_3 | Pages: No page available

10.1161/circ.132.suppl_3.17604 Get It

Introduction: Congenital long QT syndrome (LQTS) is a sudden cardiac death-predisposing genetic disorder that has a characteristic electrocardiographic signature. Specific LQTS genotypes have been associated classically with different qualitative electrocardiographic ST - T wave patterns; however, clinical recognition of these patterns could be improved by an automated and quantitative method. We therefore aimed to use a novel, quantitative T wave morphological analysis technique from 12-lead surface ECGs to identify genotype specific LQTS ECG patterns. Methods: We analyzed a genotyped cohort of 420 patients (22 ± 15.7years, 43% male) with either LQT1 (61%) or LQT2 (39%). ECG analysis was conducted using a custom T wave program to automatically detect subtle changes in T wave morphology across all 12 Leads. Classification was performed using the top three T wave features in a linear discriminant classifier by 10x10 cross-validation. Results: The top three discriminant features were (1) a steeper T wave left slope for LQT1 in lead II (2950 vs 1700 mV/ms, p < 0.0001), (2) a greater center of gravity in 1st segment of T wave in lead aVR in LQT1 (0.248 vs 0.209, p<0.0001) and (3) a smaller Tpeak - Tend/QT ratio in lead aVR in LQT1 (0.20 vs 0.24, p<0.0001). Using these top three features, we were able to successfully differentiate LQT1 and LQT2 in 79% of cases (figure 1). Conclusions: An automated morphological T wave analysis was able to discriminate between the two most common LQTS genotypes. This novel method enhances phenotypic characterization of LQT and could have a significant clinical impact on the diagnosis and management of patients with suspected LQTS.
Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
Lheureux, Stéphanie , Konstantinopoulos, Panagiotis A. , Wang, Ben X. , Gadalla, Ramy , Block, Matthew S. , Gaillard, Stéphanie , McHale, Michael , Werner, Theresa L. , Duska, Linda , Kehoe, Siobhan M., Colombo, Ilaria , Wang, Lisa , Wildman, Rachel P., Soleimani, Shirin , Lien, Scott , Wright, John, Pugh, Trevor J. , Pugh, Trevor J , Konstantinopoulos, Panagiotis A , Gaillard, Stéphanie , Matei, Daniela , Jewell, Andrea , McCourt, Carolyn Kay , Temkin, Sarah M. , Girda, Eugenia , Backes, Floor , Li, Xuan , Wildman, Rachel, Wright, John, Ohashi, Pamela S. , Brooks, David G. , Fleming, Gini F.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 14, 2022 | Volume: 10 | Issue: 3 | Pages: e004233

10.1136/jitc-2021-004233 | PMID 35288469 Get It

Background Combining immunotherapy and antiangiogenic agents is a promising treatment strategy in endometrial cancer. To date, no biomarkers for response have been identified and data on post-immunotherapy progression are lacking. We explored the combination of a checkpoint inhibitor (nivolumab) and an antiangiogenic agent (cabozantinib) in immunotherapy-naïve endometrial cancer and in patients whose disease progressed on previous immunotherapy with baseline biopsy for immune profiling. Patients and methods In this phase II trial (ClinicalTrials.gov NCT03367741, registered December 11, 2017), women with recurrent endometrial cancer were randomized 2:1 to nivolumab with cabozantinib (Arm A) or nivolumab alone (Arm B). The primary endpoint was Response Evaluation Criteria in Solid Tumors-defined progression-free survival (PFS). Patients with carcinosarcoma or prior immune checkpoint inhibitor received combination treatment (Arm C). Baseline biopsy and serial peripheral blood mononuclear cell (PBMC) samples were analyzed and associations between patient outcome and immune data from cytometry by time of flight (CyTOF) and PBMCs were explored. Results Median PFS was 5.3 (90% CI 3.5 to 9.2) months in Arm A (n=36) and 1.9 (90% CI 1.6 to 3.4) months in Arm B (n=18) (HR=0.59, 90% CI 0.35 to 0.98; log-rank p=0.09, meeting the prespecified statistical significance criteria). The most common treatment-related adverse events in Arm A were diarrhea (50%) and elevated liver enzymes (aspartate aminotransferase 47%, alanine aminotransferase 42%). In-depth baseline CyTOF analysis across treatment arms (n=40) identified 35 immune-cell subsets. Among immunotherapy-pretreated patients in Arm C, non-progressors had significantly higher proportions of activated tissue-resident (CD103+CD69+) ɣδ T cells than progressors (adjusted p=0.009). Conclusions Adding cabozantinib to nivolumab significantly improved outcomes in heavily pretreated endometrial cancer. A subgroup of immunotherapy-pretreated patients identified by baseline immune profile and potentially benefiting from combination with antiangiogenics requires further investigation.